Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.

Hermann L MüllerJohannes H M MerksBirgit GeoergerJacques GrillDarren HargraveJulia Glade BenderSridharan GururanganFariba NavidMichael JohnstonJeanette BachirMarkus C ElzeSabine Fürst-Recktenwald

Published in: Pediatric blood & cancer (2018)

Bevacizumab did not appear to have additional negative effects on growth or development of pediatric and adolescent patients with solid tumors.

Keyphrases

young adults
mental health
childhood cancer
metastatic colorectal cancer
bone mineral density
soft tissue
postmenopausal women
bone loss